Introduced
El texto subrayado se agregaría a la ley vigente. El texto tachado se eliminaría.
| By: McGee | H.B. No. 1260 |
| A BILL TO BE ENTITLED | |
| AN ACT | |
| relating to the disclosure of financial interests by and the | |
| regulation of advertising by health care practitioners who promote | |
| or facilitate the sale of drugs to consumers; providing | |
| administrative and civil penalties. | |
| BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS: | |
| SECTION 1. SHORT TITLE. This Act may be cited as the | |
| Practitioner Drug Promotion Transparency Act. | |
| SECTION 2. Subtitle A, Title 3, Occupations Code, is | |
| amended by adding Chapter 118 to read as follows: | |
| CHAPTER 118. PROMOTION AND SALE OF DRUGS BY HEALTH CARE | |
| PRACTITIONERS | |
| Sec. 118.001. DEFINITIONS. In this chapter: | |
| (1) "Advertising" means any communication made to the | |
| public or to a consumer, in any medium, that promotes the purchase | |
| or use of a drug, including a statement made on an Internet website, | |
| a social media platform, a newsletter, a subscription publication, | |
| a podcast, a broadcast, a video, a livestream, an e-mail, or a text | |
| message, and including a link, discount code, or other means of | |
| directing a consumer to a point of sale. | |
| (2) "Affiliated entity" means a person in which a | |
| health care practitioner or a member of the practitioner's | |
| immediate family holds a financial interest, including a pharmacy, | |
| telemedicine platform, distributor, wholesaler, or online | |
| retailer. | |
| (3) "Covered sale" means a sale or dispensing of a drug | |
| to a consumer in this state in which a health care practitioner has | |
| a financial interest, whether the drug is dispensed under a | |
| prescription drug order, under a statewide standing order or | |
| protocol, or without a prescription. | |
| (4) "Drug" has the meaning assigned by Section | |
| 431.002, Health and Safety Code, and includes a compounded drug. | |
| (5) "Financial interest" means any direct or indirect | |
| interest in, or expectation of, remuneration that varies with or is | |
| contingent on the sale of a drug, including: | |
| (A) an ownership or investment interest in an | |
| affiliated entity; | |
| (B) a commission, affiliate fee, referral fee, | |
| royalty, or share of revenue or profit; | |
| (C) compensation attributable to a discount | |
| code, tracking link, or similar referral mechanism; and | |
| (D) a consulting, speaking, sponsorship, or | |
| licensing fee paid by a person that manufactures, compounds, | |
| distributes, or dispenses the drug. | |
| The term does not include ownership of less than one percent of the | |
| outstanding securities of a publicly traded company, or a | |
| reasonable fee for professional services lawfully billed to a | |
| patient that does not vary with the patient's purchase of a | |
| particular drug. | |
| (6) "Health care practitioner" means an individual | |
| licensed, certified, or registered under this title who is | |
| authorized to prescribe or order a drug. | |
| (7) "Licensing authority" means the state agency that | |
| issued the health care practitioner's license, certification, or | |
| registration. | |
| (8) "Unapproved use" means the use of a drug for a | |
| disease, condition, or purpose that is not included in the drug's | |
| labeling approved by the United States Food and Drug | |
| Administration. | |
| Sec. 118.002. APPLICABILITY. This chapter applies to a | |
| health care practitioner who, directly or through an affiliated | |
| entity or agent, advertises a drug in which the practitioner has a | |
| financial interest or facilitates a covered sale, regardless of | |
| whether the practitioner has a practitioner-patient relationship | |
| with the consumer. | |
| Sec. 118.003. REQUIRED DISCLOSURES IN ADVERTISING AND AT | |
| POINT OF SALE. (a) A health care practitioner who advertises a | |
| drug in which the practitioner has a financial interest shall | |
| include in the advertising a clear and conspicuous statement that: | |
| (1) the practitioner has a financial interest in the | |
| sale of the drug; | |
| (2) describes the nature of the financial interest, | |
| including whether the practitioner owns or is compensated by the | |
| seller; and | |
| (3) if the advertising promotes an unapproved use, | |
| states: "This drug has not been approved by the U.S. Food and Drug | |
| Administration for the use described. Talk to a licensed health | |
| care provider who does not profit from this sale before taking it." | |
| (b) Before a covered sale is completed through an Internet | |
| website or other remote ordering system, the seller and the health | |
| care practitioner shall ensure the consumer is shown, on a page the | |
| consumer must view before payment: | |
| (1) the disclosures required by Subsection (a); | |
| (2) the name, address, and license number of each | |
| health care practitioner who has a financial interest in the sale; | |
| (3) the name, license number, and physical address of | |
| the pharmacy or other person that will dispense the drug; | |
| (4) a statement that the consumer may obtain the drug, | |
| if lawfully available, from any pharmacy of the consumer's | |
| choosing; and | |
| (5) the address of an Internet website maintained by | |
| the licensing authority where the consumer may file a complaint. | |
| (c) A statement required by this section is clear and | |
| conspicuous only if it is: | |
| (1) in written advertising, displayed in the body of | |
| the advertising itself, and not only in a linked page, profile, or | |
| caption that requires the consumer to expand or click, in a type | |
| size at least as large as the largest type used to describe the | |
| drug's benefits; | |
| (2) in audio or video advertising, spoken at the | |
| beginning of the communication and, for video, also displayed on | |
| screen for not less than five seconds; and | |
| (3) in a livestream or recurring broadcast, repeated | |
| at least once every 15 minutes during which the drug is promoted. | |
| (d) The licensing authorities, in consultation with the | |
| Health Professions Council, may adopt rules prescribing additional | |
| format requirements for disclosures on specific media platforms. | |
| Sec. 118.004. PUBLIC REPORTING OF FINANCIAL INTERESTS. (a) | |
| Not later than March 1 of each year, a health care practitioner who | |
| had a financial interest in a covered sale or who advertised a drug | |
| in which the practitioner had a financial interest during the | |
| preceding calendar year shall file a report with the practitioner's | |
| licensing authority that includes: | |
| (1) the name and address of each affiliated entity and | |
| each person from whom the practitioner received remuneration | |
| described by Section 118.001(5); | |
| (2) each drug advertised or sold, and each disease or | |
| condition for which the practitioner promoted the drug; | |
| (3) the total remuneration received, reported in | |
| ranges prescribed by rule of the licensing authority; and | |
| (4) the approximate number of covered sales. | |
| (b) The licensing authority shall make the information | |
| described by Subsections (a)(1), (2), and (3) available to the | |
| public on its Internet website, including in any public profile of | |
| the practitioner maintained by the licensing authority. | |
| (c) Information described by Subsection (a)(4) is | |
| confidential, except that it may be disclosed in a disciplinary | |
| proceeding or an enforcement action under this chapter. | |
| Sec. 118.005. UNSUPPORTED CLAIMS PROHIBITED. (a) A health | |
| care practitioner may not, in advertising for a drug in which the | |
| practitioner has a financial interest, represent that the drug | |
| prevents, treats, mitigates, or cures a disease or condition | |
| unless: | |
| (1) that use is included in the drug's labeling | |
| approved by the United States Food and Drug Administration; or | |
| (2) at the time the representation is made, the | |
| representation is substantiated by competent and reliable | |
| scientific evidence, which must include at least one adequate and | |
| well-controlled clinical study in humans, published in a | |
| peer-reviewed scientific or medical journal, that demonstrates the | |
| claimed effect for that disease or condition. | |
| (b) A representation is not substantiated under Subsection | |
| (a)(2) if it is based solely on laboratory or in vitro data, animal | |
| studies, the drug's mechanism of action, anecdotal reports, or the | |
| practitioner's personal clinical experience. | |
| (c) The health care practitioner bears the burden of | |
| producing the substantiation required by Subsection (a)(2) in a | |
| disciplinary proceeding or enforcement action under this chapter. | |
| Sec. 118.006. NONPRESCRIPTION AND REMOTE SALES. (a) A | |
| health care practitioner may not hold a financial interest in, or | |
| accept remuneration from any person in connection with, the | |
| dispensing of a drug by a pharmacist under a statewide standing | |
| order or protocol that authorizes dispensing without a | |
| patient-specific prescription drug order, including dispensing | |
| under Chapter 446, Health and Safety Code. | |
| (b) A health care practitioner who has a financial interest | |
| in a covered sale may not issue a prescription drug order for that | |
| sale unless the practitioner has established a | |
| practitioner-patient relationship that meets the standard of care, | |
| as provided by Chapter 111. A practitioner-patient relationship is | |
| not established for purposes of this subsection solely by the | |
| consumer's completion of an online questionnaire or by the | |
| consumer's purchase of the drug. | |
| (c) Before issuing a prescription drug order for a covered | |
| sale, the health care practitioner shall provide the patient the | |
| written disclosures required by Section 118.003(b) and obtain the | |
| patient's acknowledgment, which may be electronic, and shall retain | |
| the acknowledgment in the patient's medical record. | |
| Sec. 118.007. EXCEPTIONS. This chapter does not apply to: | |
| (1) a statement, opinion, publication, testimony, or | |
| other communication by a health care practitioner who does not have | |
| a financial interest in the sale of the drug that is the subject of | |
| the communication; | |
| (2) a communication made solely to another health care | |
| practitioner in a professional or scientific context, including a | |
| peer-reviewed publication or a presentation at a professional | |
| conference, that does not include a point of sale or referral | |
| mechanism; | |
| (3) a drug sample provided without charge in | |
| compliance with federal law; | |
| (4) the provision or dispensing of a drug by a | |
| physician in compliance with Chapter 158, other than through | |
| advertising to the public; or | |
| (5) a drug administered to a patient in a hospital, | |
| ambulatory surgical center, or the practitioner's office as part of | |
| a course of treatment. | |
| Sec. 118.008. ENFORCEMENT; PENALTIES. (a) A violation of | |
| this chapter by a health care practitioner is: | |
| (1) unprofessional conduct and a ground for | |
| disciplinary action by the practitioner's licensing authority | |
| under the law governing the practitioner's license, including | |
| Section 164.051 for a physician; and | |
| (2) a false, misleading, or deceptive act or practice | |
| under Section 17.46, Business & Commerce Code, and is actionable | |
| under Subchapter E, Chapter 17, Business & Commerce Code. | |
| (b) A person who violates this chapter is liable to the | |
| state for a civil penalty of not more than $10,000 for each | |
| violation. Each advertisement disseminated and each covered sale | |
| made in violation of this chapter constitutes a separate violation. | |
| (c) The maximum civil penalty under Subsection (b) is | |
| doubled for a violation of Section 118.005 that relates to a disease | |
| or condition that is the subject of a public health disaster | |
| declared under Section 81.003, Health and Safety Code, or a state of | |
| disaster declared under Chapter 418, Government Code, if the | |
| violation occurs while the declaration is in effect. | |
| (d) The attorney general, or the district attorney or county | |
| attorney of a county in which a consumer who received the | |
| advertising or purchased the drug resides, may bring an action to | |
| recover a civil penalty, obtain restitution for affected consumers, | |
| or obtain injunctive relief under this chapter. A prosecuting | |
| attorney who prevails in an action under this subsection may | |
| recover reasonable attorney's fees and investigative costs. | |
| (e) A licensing authority shall refer a complaint alleging a | |
| violation of this chapter to the attorney general and to the | |
| appropriate local prosecuting attorney not later than the 30th day | |
| after the date the licensing authority determines the complaint is | |
| not frivolous. | |
| (f) The remedies provided by this chapter are cumulative of | |
| any other remedy provided by law. | |
| Sec. 118.009. RULES. Each licensing authority shall adopt | |
| rules as necessary to implement this chapter. The Health | |
| Professions Council shall coordinate the rules to ensure consistent | |
| disclosure standards across licensing authorities. | |
| SECTION 3. Chapter 446, Health and Safety Code, is amended | |
| by adding Sections 446.003 and 446.004 to read as follows: | |
| Sec. 446.003. REFERRAL PAYMENTS PROHIBITED; DISCLOSURE. | |
| (a) A pharmacist or pharmacy may not pay or offer remuneration of | |
| any kind to a health care practitioner, as defined by Section | |
| 118.001, Occupations Code, or to any other person in exchange for | |
| referring, directing, or recruiting a consumer to purchase | |
| ivermectin dispensed under Section 446.001. | |
| (b) A pharmacist who dispenses ivermectin under Section | |
| 446.001 shall provide the consumer a written notice stating: | |
| "Ivermectin has not been approved by the U.S. Food and Drug | |
| Administration to prevent or treat COVID-19, hantavirus, or other | |
| viral infections. Taking more than the recommended dose can cause | |
| serious harm." | |
| (c) A violation of Subsection (a) is grounds for | |
| disciplinary action by the Texas State Board of Pharmacy and | |
| constitutes a violation of Chapter 102, Occupations Code. | |
| Sec. 446.004. ANNUAL REPORT. Not later than March 1 of each | |
| year, each pharmacy that dispensed ivermectin under Section 446.001 | |
| during the preceding calendar year shall report to the Texas State | |
| Board of Pharmacy, in the form prescribed by the board, the number | |
| of doses dispensed and any adverse event reported to the pharmacy. | |
| The board shall publish an aggregate summary of the reports on its | |
| Internet website. | |
| SECTION 4. Section 154.006(a), Occupations Code, is amended | |
| by adding Subdivision (__) to read as follows: | |
| (__) the information required to be made public under Section | |
| 118.004, as reported by the physician; | |
| SECTION 5. Not later than December 1, 2027, each licensing | |
| authority shall adopt the rules required by Section 118.009, | |
| Occupations Code, as added by this Act. | |
| SECTION 6. (a) Sections 118.003, 118.005, and 118.006, | |
| Occupations Code, as added by this Act, apply only to advertising | |
| disseminated or a sale made on or after January 1, 2028. | |
| (b) A health care practitioner is not required to file a | |
| report under Section 118.004, Occupations Code, as added by this | |
| Act, before March 1, 2029. | |
| (c) Section 446.003, Health and Safety Code, as added by | |
| this Act, applies only to remuneration paid or offered on or after | |
| January 1, 2028. | |
| SECTION 7. SEVERABILITY. If any provision of this Act or | |
| its application to any person or circumstance is held invalid, the | |
| invalidity does not affect other provisions or applications of this | |
| Act that can be given effect without the invalid provision or | |
| application, and to this end the provisions of this Act are | |
| severable. | |
| SECTION 8. This Act takes effect September 1, 2027. |
Texto oficial de la Legislatura de Texas. El formato se adaptó para leerlo en Ratifi.